Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bayer AG has launched a clinical study titled Open-label Study of Androgen Receptor Inhibition With Darolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm. The study aims to evaluate the efficacy of combining darolutamide with ADT compared to ADT alone in treating metastatic hormone-sensitive prostate cancer (mHSPC), focusing on progression-free survival as a key measure.
The intervention involves administering darolutamide, a drug that blocks androgen receptors, alongside ADT, which reduces androgen hormone levels. This combination is being tested against historical data from a previous study where patients received only ADT.
The study is designed as an interventional, single-group assignment without masking, primarily for treatment purposes. Participants receive darolutamide and ADT, while the control data is derived from the CHAARTED trial.
The study commenced on November 4, 2021, with its primary completion and estimated completion dates yet to be disclosed. The latest update was submitted on August 8, 2025, indicating ongoing progress.
This study update could influence Bayer’s stock performance by potentially enhancing investor confidence if the results demonstrate significant clinical benefits. The competitive landscape includes other pharmaceutical companies developing similar treatments, which could impact market dynamics.
The study remains active, with further details accessible on the ClinicalTrials portal.